Pfizer Inc. $PFE Shares Purchased by Beacon Harbor Wealth Advisors Inc.

Beacon Harbor Wealth Advisors Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 179.6% in the 1st quarter, HoldingsChannel reports. The fund owned 302,840 shares of the biopharmaceutical company’s stock after acquiring an additional 194,544 shares during the period. Pfizer accounts for about 1.8% of Beacon Harbor Wealth Advisors Inc.’s portfolio, making the stock its 21st biggest holding. Beacon Harbor Wealth Advisors Inc.’s holdings in Pfizer were worth $8,504,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sequoia Financial Advisors LLC lifted its position in shares of Pfizer by 4.5% during the 1st quarter. Sequoia Financial Advisors LLC now owns 354,125 shares of the biopharmaceutical company’s stock worth $9,944,000 after purchasing an additional 15,289 shares during the last quarter. Villere ST Denis J & Co. LLC lifted its position in shares of Pfizer by 14.0% during the 1st quarter. Villere ST Denis J & Co. LLC now owns 574,968 shares of the biopharmaceutical company’s stock worth $16,145,000 after buying an additional 70,613 shares during the last quarter. Relyea Zuckerberg Hanson LLC boosted its holdings in shares of Pfizer by 4.9% in the 1st quarter. Relyea Zuckerberg Hanson LLC now owns 15,846 shares of the biopharmaceutical company’s stock valued at $445,000 after buying an additional 736 shares in the last quarter. KLCM Advisors Inc. grew its position in shares of Pfizer by 0.8% in the 1st quarter. KLCM Advisors Inc. now owns 166,141 shares of the biopharmaceutical company’s stock valued at $4,665,000 after buying an additional 1,323 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS raised its stake in Pfizer by 9.3% during the 1st quarter. Kornitzer Capital Management Inc. KS now owns 1,357,315 shares of the biopharmaceutical company’s stock worth $38,113,000 after acquiring an additional 115,759 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.1%

Shares of Pfizer stock opened at $24.21 on Friday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a market cap of $138.01 billion, a P/E ratio of 18.48 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a fifty day moving average of $25.37 and a two-hundred day moving average of $26.18.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.97 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

Analyst Ratings Changes

Several equities analysts have issued reports on PFE shares. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a report on Tuesday, June 9th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Citigroup raised their price target on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Finally, Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.56.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer, expanding the label for a key Pfizer/Astellas regimen and potentially opening the door to more sales in oncology. Article: U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
• Positive Sentiment: Pfizer’s oncology story also got incremental attention from a completed lorlatinib lung cancer study and other clinical updates, which keep investors focused on the company’s pipeline rather than only its mature products. Article: Pfizer’s Lorlatinib Lung Cancer Study Wraps Up, Offering Fresh Signals for PFE Investors
• Neutral Sentiment: Bank of America lowered its price target on Pfizer to $26 from $27 while keeping a neutral rating, signaling limited upside but no major change in its overall stance. Article: Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00.
• Negative Sentiment: Several market commentary pieces highlighted concerns about Pfizer’s growth outlook and mixed second-quarter expectations, including skepticism about how quickly Seagen-related benefits will show up in results. Article: Pfizer Poised for Mixed Second Quarter, RBC Says

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.